Also Clin1 systemic sclerosis – interstitial lung disease, Clin1 liver fibrosis; BLD-2184 Clin0 neurodegenerative diseases
Blade Therapeutics is developing antifibrotic treatment strategies to treat a variety of diseases. Fibrotic and neurodegenerative diseases impact millions of people worldwide. Foundational to the cell and tissue damage of fibrotic diseases are autotaxin and calpain biology. Blade’s pipeline includes oral, small molecular therapies that include a non-competitive autotaxin inhibitor and inhibitors of diemric calpains designed to treat patients with lung, liver and cardiac fibrosis. Blade’s lead candidate, Cudetaxestat, is Phase 2 ready for the treatment of Idiopathic Pulmonary Fibrosis. Cudetaxestat is a non-competitive autotaxin inhibitor with robust preclinical antifibrotic activity with good pharmacokinetics.